Systematic review and meta‐analysis of potential pleiotropic effects of sevelamer in chronic kidney disease: Beyond phosphate control

Sevelamer, has been shown to have many pleiotropic actions on lipid panel, various inflammatory markers, and blood glucose levels in chronic kidney disease patients. We conducted a systematic review and meta‐analysis to compare these pleiotropic effects of sevelamer to other phosphate binders used i...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology (Carlton, Vic.) Vic.), 2022-04, Vol.27 (4), p.337-354
Main Authors: Basutkar, Roopa Satyanarayan, Varghese, Resia, Mathew, Nina Kallanthanath, Sankar Indira, Prithika, Viswanathan, Balasubramaniam, Sivasankaran, Ponnusankar
Format: Article
Language:English
Subjects:
anti‐inflammatory effects
calcium
Calcium phosphates
Cholesterol
chronic kidney disease
Clinical trials
Glucose
HbA1C
Hemoglobin
Inflammation
Kidney diseases
lipid effects
Meta-analysis
sevelamer
Statistical analysis
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sevelamer, has been shown to have many pleiotropic actions on lipid panel, various inflammatory markers, and blood glucose levels in chronic kidney disease patients. We conducted a systematic review and meta‐analysis to compare these pleiotropic effects of sevelamer to other phosphate binders used in chronic kidney disease patients. The relevant randomized controlled trials published from 1 January 2001 to 31 November 2019 on the following databases: Cochrane Central Register of Controlled Trials published in The Cochrane Library, PubMed, Scopus and Google Scholar were identified. All the included studies were independently assessed for eligibility and risk of bias. The modified data extraction form of Cochrane was used. This review included 44 studies for qualitative analysis and 28 reports for quantitative analysis. A meta‐analysis of three studies (n = 180) showed that glycated haemoglobin had significantly decreased in sevelamer‐treated patients (MD: 0.5%; p = 
ISSN:1320-5358
1440-1797
DOI:10.1111/nep.14011